Immunologic Identifiers May Be Related to Relapse in Chronic Myeloid Leukemia
Posted: Wednesday, January 8, 2020
A group of identified biomarkers may be used as predictors of treatment-free remission outcome in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors, according to immunologic study results presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando (Abstract 191). Valentín Garcia-Gutiérrez, MD, PhD, of the Hospital Universitario Ramon y Cajal, and colleagues suggest further studies with larger cohorts are warranted to support their findings.
“Characterization of the immune response developed in patients with CML due to treatment with different tyrosine kinase inhibitors may be relevant to predict the success of treatment discontinuation,” the authors commented.
Samples from 73 patients with CML and 20 healthy donors were examined. Flow cytometry was used to assess the patients’ peripheral blood mononuclear cells. The authors examined 45 patients with CML who had been on tyrosine kinase inhibitors for at least 9 months; 17 patients off tyrosine kinase inhibitors for at least 7 months who had a deep molecular response; 7 patients off tyrosine kinase inhibitors for at least 1 year and 4 months who relapsed during treatment-free remission; and 4 patients who were recently diagnosed with CML and were still untreated.
“We have determined that the modulation of the expression of the following markers may be used as potential predictors of treatment-free remission outcome: CD56+ < 4%; CD3-CD56+CD16+ > 7%; CD56+NKG2D+ > 24%; CD8+TCRgd+ > 7%; CD8-TCRgd+ > 4%; and CD86+ < 20%,” concluded the authors.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.